STOCK TITAN

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Nurix Therapeutics (NRIX) reported Q3 fiscal 2024 financial results and provided a corporate update. Key highlights include:

1. Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia and other B-cell malignancies

2. Reinitiated enrollment for NX-2127 in a Phase 1a/b oncology trial

3. Presented preclinical data on Degrader-Antibody Conjugates (DACs)

4. Cash and marketable securities of $457.5 million

Financial results: Collaboration revenue was $12.6 million, down from $18.5 million in Q3 2023. R&D expenses increased to $55.5 million from $47.9 million. Net loss was $49.0 million or ($0.67) per share.

The company anticipates clinical data readouts in Q4 2024 and initiation of pivotal studies for NX-5948 in 2025.

Nurix Therapeutics (NRIX) ha riportato i risultati finanziari del terzo trimestre dell'anno fiscale 2024 e ha fornito un aggiornamento aziendale. Tra i punti salienti:

1. Avviata l'espansione della dose della Fase 1b di NX-5948 nella leucemia linfocitica cronica e in altre neoplasie a cellule B.

2. Riavviato il reclutamento per NX-2127 in uno studio oncologico di Fase 1a/b.

3. Presentati dati preclinici sui Coniugati Anticorpo Degradante (DACs).

4. Liquidità e titoli quotati per un totale di 457,5 milioni di dollari.

Risultati finanziari: Le entrate da collaborazioni sono state di 12,6 milioni di dollari, in calo rispetto ai 18,5 milioni di dollari del terzo trimestre 2023. Le spese per R&S sono aumentate a 55,5 milioni di dollari rispetto ai 47,9 milioni di dollari. La perdita netta è stata di 49,0 milioni di dollari, pari a ($0,67) per azione.

L'azienda prevede letture di dati clinici nel quarto trimestre del 2024 e l'avvio di studi fondamentali per NX-5948 nel 2025.

Nurix Therapeutics (NRIX) informó los resultados financieros del tercer trimestre del ejercicio fiscal 2024 y ofreció una actualización corporativa. Los puntos destacados incluyen:

1. Iniciada la expansión de dosis de la Fase 1b de NX-5948 en leucemia linfocítica crónica y otras malignidades de células B.

2. Reanudado el reclutamiento para NX-2127 en un ensayo oncológico de Fase 1a/b.

3. Presentados datos preclínicos sobre Conjugados de Anticuerpos Degradantes (DACs).

4. Efectivo y valores negociables por un total de 457,5 millones de dólares.

Resultados financieros: Los ingresos por colaboraciones fueron de 12,6 millones de dólares, en comparación con 18,5 millones de dólares en el tercer trimestre de 2023. Los gastos de I+D aumentaron a 55,5 millones de dólares desde 47,9 millones de dólares. La pérdida neta fue de 49,0 millones de dólares, o ($0,67) por acción.

La empresa anticipa resultados de datos clínicos en el cuarto trimestre de 2024 y el inicio de estudios clave para NX-5948 en 2025.

Nurix Therapeutics (NRIX)는 2024 회계연도 3분기 재무 결과를 발표하고 기업 업데이트를 제공했습니다. 주요 하이라이트는 다음과 같습니다:

1. 만성 림프구 백혈병 및 기타 B세포 악성종양에서 NX-5948의 1b상 용량 확장을 시작했습니다.

2. NX-2127에 대한 1a/b상 종양학 시험의 참여를 재개했습니다.

3. 분해 항체 접합체(DACs)에 대한 전임상 데이터를 발표했습니다.

4. 현금 및 유가증권의 총액은 4억 5750만 달러입니다.

재무 결과: 협력 수익은 1260만 달러로, 2023년 3분기의 1850만 달러에서 감소했습니다. 연구개발 비용은 4790만 달러에서 5550만 달러로 증가했습니다. 순손실은 4900만 달러 또는 주당 ($0.67)입니다.

회사는 2024년 4분기에 임상 데이터 결과 발표를 예상하고 있으며, 2025년에 NX-5948에 대한 주요 연구를 시작할 계획입니다.

Nurix Therapeutics (NRIX) a publié les résultats financiers du troisième trimestre de l'exercice fiscal 2024 et a fourni une mise à jour sur l'entreprise. Les faits marquants incluent :

1. Début de l'expansion de dose de la phase 1b de NX-5948 dans la leucémie lymphocytaire chronique et d'autres cancers des cellules B.

2. Reprise du recrutement pour NX-2127 dans un essai oncologique de phase 1a/b.

3. Présentation de données précliniques sur les conjugués anticorps dégradants (DACs).

4. Trésorerie et titres négociables s'élevant à 457,5 millions de dollars.

Résultats financiers : Les revenus de collaboration étaient de 12,6 millions de dollars, en baisse par rapport à 18,5 millions de dollars au troisième trimestre 2023. Les dépenses de R&D ont augmenté à 55,5 millions de dollars contre 47,9 millions de dollars. La perte nette s'élevait à 49,0 millions de dollars ou ($0,67) par action.

L'entreprise prévoit des résultats de données cliniques au quatrième trimestre de 2024 et le lancement d'études pivot pour NX-5948 en 2025.

Nurix Therapeutics (NRIX) hat die finanziellen Ergebnisse für das dritte Quartal des Geschäftsjahres 2024 veröffentlicht und ein Unternehmensupdate gegeben. Wichtige Highlights sind:

1. Die Phase-1b-Dosiserweiterung von NX-5948 bei chronischer lymphatischer Leukämie und anderen B-Zell-Malignitäten wurde initiiert.

2. Die Rekrutierung für NX-2127 wurde in einer Phase-1a/b-Onkologie-Studie wieder aufgenommen.

3. Vorläufige Daten zu Degrader-Antikörper-Konjugaten (DACs) wurden präsentiert.

4. Bargeld und marktfähige Wertpapiere in Höhe von 457,5 Millionen Dollar.

Finanzergebnisse: Die Kooperationsumsätze betrugen 12,6 Millionen Dollar, ein Rückgang von 18,5 Millionen Dollar im dritten Quartal 2023. Die F&E-Ausgaben stiegen auf 55,5 Millionen Dollar von 47,9 Millionen Dollar. Der Nettoverlust betrug 49,0 Millionen Dollar oder ($0,67) pro Aktie.

Das Unternehmen erwartet im vierten Quartal 2024 klinische Datenauswertungen und den Beginn von entscheidenden Studien für NX-5948 im Jahr 2025.

Positive
  • Initiated Phase 1b dose expansion of NX-5948 in multiple indications
  • Reinitiated enrollment for NX-2127 in Phase 1a/b trial
  • Strong cash position of $457.5 million
  • Anticipating clinical data readouts in Q4 2024
  • Planning to initiate pivotal studies for NX-5948 in 2025
Negative
  • Collaboration revenue decreased from $18.5 million to $12.6 million year-over-year
  • R&D expenses increased from $47.9 million to $55.5 million year-over-year
  • Net loss increased from $37.0 million to $49.0 million year-over-year

Insights

Nurix Therapeutics' Q3 FY2024 results show a mixed financial picture. Revenue decreased to $12.6 million from $18.5 million year-over-year, primarily due to the end of the initial research term for certain drug targets in the Gilead collaboration. However, this was partially offset by new revenue from the Pfizer collaboration.

R&D expenses increased to $55.5 million from $47.9 million, reflecting accelerated clinical trial activities. The net loss widened to $49.0 million ($0.67 per share) compared to $37.0 million ($0.68 per share) in the previous year.

Importantly, Nurix maintains a strong cash position of $457.5 million, slightly up from $452.5 million in the previous quarter. This robust cash reserve provides a significant runway for ongoing clinical trials and pipeline development, potentially through several key milestones in 2024 and 2025.

The company's focus on executing its clinical programs, particularly NX-5948 and NX-2127, along with its collaborations with major pharmaceutical companies, positions it well for potential value creation in the near to medium term. However, investors should monitor the increasing R&D expenses and widening losses as the company progresses its pipeline.

Nurix's clinical progress is noteworthy, particularly in B-cell malignancies. The initiation of Phase 1b dose expansion for NX-5948 in chronic lymphocytic leukemia (CLL) with FDA Fast Track Designation is significant. This expansion into CLL, Waldenstrom's macroglobulinemia, follicular lymphoma and marginal zone lymphoma demonstrates the potential broad applicability of their BTK degrader technology.

The re-initiation of NX-2127's Phase 1a/b trial with a new chirally controlled drug product is a positive development following the FDA's lifting of the partial clinical hold. This showcases the company's ability to address regulatory concerns and continue advancing its pipeline.

The presentation of preclinical data on Degrader-Antibody Conjugates (DACs) is intriguing. If successful, this technology could represent a significant advancement in targeted protein degradation, potentially offering improved therapeutic index and broader applicability than standard antibody-drug conjugates (ADCs).

With multiple data readouts expected in Q4 2024 and pivotal studies planned for 2025, Nurix is approaching critical inflection points that could significantly impact its valuation and potential for partnerships or acquisitions in the oncology space.

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA

Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom’s macroglobulinemia, follicular lymphoma and marginal zone lymphoma patients

Reinitiated enrollment for NX-2127 in a Phase 1a/b trial in oncology

Presented preclinical data on Degrader-Antibody Conjugates (DACs), a new class of therapeutics

Well capitalized with cash and marketable securities of $457.5 million

SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the third quarter ended August 31, 2024, and provided a corporate update.

“We continue to make great progress and remain focused on execution as we advance our pipeline of wholly owned and partnered programs in oncology, inflammation and immunology,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “As we approach the end of the year, we are well capitalized and look forward to building further momentum as we head into clinical data readouts in the fourth quarter of 2024 and the initiation of pivotal studies of NX-5948 in 2025.”

Recent Business Highlights

  • Expanded clinical development of NX-5948: In the third quarter of 2024, Nurix initiated the Phase 1b portion of its ongoing Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies. The Phase 1b expansion includes a randomization to a low dose (200mg QD) or a high dose (600mg QD) of NX-5948 in patients with chronic lymphocytic leukemia (CLL) who have been treated with at least two prior regimens including a Bruton’s tyrosine kinase (BTK) inhibitor and a BCL2 inhibitor. This is the patient population for which the FDA granted Nurix Fast Track designation in January 2024. Cohorts were also initiated to evaluate NX-5948 in patients with Waldenstrom’s macroglobulinemia (WM), marginal zone lymphoma and follicular lymphoma.
  • Re-initiated enrollment in NX-2127 Phase 1a/b trial: Nurix recently reinitiated enrollment with its new chirally controlled drug product in a standard dose escalation study within the current Phase 1a/1b trial. As previously announced, in March 2024, the U.S. Food and Drug Administration (FDA) lifted a manufacturing-related, partial clinical hold on the NX-2127 clinical trial. Patients enrolled prior to the partial clinical hold who are deriving clinical benefit continue to receive uninterrupted treatment with the original drug product.
  • Presented early preclinical data from ongoing collaboration with Pfizer to develop Degrader-Antibody Conjugates, a new class of therapeutics: On September 10, 2024, at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit, Nurix’s chief scientific officer, Gwenn M. Hansen, Ph.D., presented an outline of the advantages of DACs, Nurix’s matrixed approach to the generation and optimization of DACs using its DELigase platform, and early preclinical data demonstrating cell-type selective degradation of targeted proteins by DACs. Nurix believes that DACs may represent a next generation of antibody drug conjugate (ADC) technology that could broaden its use in oncology and potentially other indications. DACs combine the catalytic activity of a targeted protein degrader with the tissue specificity of an antibody which has the potential to provide improved therapeutic index and broader applicability than standard ADCs and which can potentially be applied to any protein target in any tissue.

Upcoming Program Highlights*

NX-5948: NX-5948 is an investigational, orally bioavailable degrader of BTK that is currently being evaluated in the Phase 1b portion of a Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies. By year-end 2024, Nurix plans to present additional clinical data from this study for patients with CLL. Later this month, at the 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM 12), Nurix will present a clinical update from this study on patients with WM. Additional information on the Phase 1a/b clinical trial can be accessed at www.clinicaltrials.gov (NCT05131022).

Nurix is also conducting a Phase 1 healthy volunteer study to assess food effects and drug-drug interactions in anticipation of initiating pivotal development in 2025. Additional information on this Phase 1 clinical trial can be accessed at www.clinicaltrials.gov (NCT06593457).

Nurix continues to lay the groundwork for indication selection in autoimmune and inflammatory diseases and expects to complete ongoing preclinical studies in 2024 that can enable an investigational new drug (IND) application for NX-5948 in autoimmune indications. An abstract titled “NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases” was accepted for a poster presentation at the upcoming annual meeting of the American College of Rheumatology (ACR 2024), being held November 14–19, 2024, in Washington, D.C.

NX-2127: NX-2127 is an orally bioavailable BTK degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B‑cell malignancies. Nurix is conducting a Phase 1a/b clinical trial of NX-2127, which includes Phase 1b expansion cohorts focused on patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Nurix recently introduced a new chirally controlled drug product, which is being evaluated in a dose escalation within this Phase 1a/b trial. Future clinical updates are anticipated in 2025. Additional information on the clinical trial can be accessed at www.clinicaltrials.gov (NCT04830137).

NX-1607: NX-1607 is an orally bioavailable inhibitor of the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CBL-B) for immuno-oncology indications, including a range of solid tumor types and lymphoma. Nurix is evaluating NX-1607 in an ongoing Phase 1 trial in monotherapy and in a combination cohort utilizing paclitaxel in adults in a range of oncology indications. This study includes a thorough investigation of both dose and schedule in Phase 1a. Nurix anticipates providing a program update by year-end 2024. Additional information on the clinical trial can be accessed at www.clinicaltrials.gov (NCT05107674).

GS-6791 (previously NX-0479): GS-6791 is a potent, selective, oral IRAK4 degrader. Degradation of IRAK4 by GS-6791 has potential applications in the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix’s partner, Gilead, is responsible for conducting IND-enabling studies and advancing this program to clinical development. An abstract titled “IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model” was accepted for a poster presentation at ACR 2024.

STAT6 degrader: In April 2024, Nurix announced an extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of transcription 6), a key drug target in type 2 inflammation, with the goal of nominating a development candidate in the first year of the extended term. Nurix remains on track for this goal.

Continued pipeline advancement of strategic collaborations with Gilead, Sanofi and Pfizer: Nurix expects to continue to achieve substantial research collaboration milestones throughout the terms of its collaborations with Gilead, Sanofi and Pfizer.

* Expected timing of events throughout this press release is based on calendar year quarters.

Fiscal Third Quarter 2024 Financial Results

Collaboration revenue for the three months ended August 31, 2024, was $12.6 million compared with $18.5 million for the three months ended August 31, 2023. Revenue from the collaboration with Gilead decreased as the initial research term for certain drug targets ended. The decrease was offset by an increase in revenue from the collaboration agreement with Pfizer that was entered into in the fourth quarter of fiscal year 2023.

Research and development expenses for the three months ended August 31, 2024, were $55.5 million compared with $47.9 million for the three months ended August 31, 2023. The increase was primarily due to clinical and contract manufacturing costs as Nurix continued to accelerate the enrollment of NX-5948 and progress its other clinical trial programs for NX-2127 and NX-1607.

General and administrative expenses for the three months ended August 31, 2024, were $11.7 million compared with $10.6 million for the three months ended August 31, 2023. The increase was primarily due to an increase in professional service and consulting costs.

Net loss for the three months ended August 31, 2024, was $49.0 million, or ($0.67) per share, compared with $37.0 million, or ($0.68) per share, for the three months ended August 31, 2023.

Cash, cash equivalents and marketable securities was $457.5 million as of August 31, 2024, compared to $452.5 million as of May 31, 2024.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Forward-Looking Statements

This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: Nurix’s future financial or business performance; Nurix’s future plans, prospects and strategies; Nurix’s plans and expectations with respect to its current and prospective drug candidates; the tolerability, safety profile, therapeutic potential and other advantages of Nurix’s drug candidates; the planned timing and conduct of Nurix’s clinical trials; the planned timing for the provision of updates and findings from Nurix’s preclinical studies and clinical trials; the potential benefits of and Nurix’s expectations with respect to its strategic collaborations, including the achievement of research milestones; and the potential benefits and advantages of Nurix’s scientific approach, DELigase™ platform and Degrader-Antibody Conjugates. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions regarding the future of Nurix’s business, its future plans and strategies, its development plans, its preclinical and clinical results, future conditions and other factors Nurix believes are appropriate in the circumstances. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) whether Nurix will be able to advance its drug candidates, obtain regulatory approval of and ultimately commercialize its drug candidates; (ii) uncertainties related to the timing and results of preclinical studies and clinical trials; (iii) whether Nurix will be able to fund development activities and achieve development goals; (iv) uncertainties related to the timing and receipt of payments from Nurix’s collaboration partners, including milestone payments and royalties on future product sales; (v) the impact of global business, political and macroeconomic conditions, cybersecurity events, instability in the banking system, and global events, including regional conflicts around the world, on Nurix’s business, clinical trials, financial condition, liquidity and results of operations; (vi) whether Nurix will be able to protect intellectual property and (vii) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2024, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:

Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

- More -

 
Nurix Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
    
 Three Months Ended Nine Months Ended
 August 31,August 31,
 2024 2023 2024 2023
Revenue:       
Collaboration revenue$12,588  $18,467  $41,265  $41,828 
License revenue          20,000 
Total revenue 12,588   18,467   41,265   61,828 
Operating expenses:       
Research and development 55,481   47,856   154,408   139,435 
General and administrative 11,718   10,623   35,227   32,122 
Total operating expenses 67,199   58,479   189,635   171,557 
Loss from operations (54,611)  (40,012)  (148,370)  (109,729)
Interest and other income, net 5,737   3,030   13,612   7,737 
Loss before income taxes (48,874)  (36,982)  (134,758)  (101,992)
Provision for income taxes 82      262    
Net loss$(48,956) $(36,982) $(135,020) $(101,992)
Net loss per share, basic and diluted$(0.67) $(0.68) $(2.13) $(1.88)
Weighted-average number of shares outstanding, basic and diluted 72,779,381   54,390,859   63,384,174   54,227,491 
        


 
Nurix Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
    
 August 31, November 30,
 2024 2023
Assets   
Current assets:   
Cash and cash equivalents$99,044  $54,627 
Marketable securities, current 349,008   233,281 
Prepaid expenses and other current assets 7,991   7,595 
Total current assets 456,043   295,503 
Marketable securities, non-current 9,472   7,421 
Operating lease right-of-use assets 27,083   31,142 
Property and equipment, net 17,069   16,808 
Restricted cash 901   901 
Other assets 3,032   3,823 
Total assets$513,600  $355,598 
Liabilities and stockholders’ equity   
Current liabilities:   
Accounts payable$3,918  $6,401 
Accrued expenses and other current liabilities 27,828   24,970 
Operating lease liabilities, current 6,553   7,489 
Deferred revenue, current 47,997   48,098 
Total current liabilities 86,296   86,958 
Operating lease liabilities, net of current portion 20,590   23,125 
Deferred revenue, net of current portion 29,858   45,022 
Total liabilities 136,744   155,105 
Stockholders’ equity:   
Common stock 67   49 
Additional paid-in-capital 1,056,665   746,299 
Accumulated other comprehensive loss 344   (655)
Accumulated deficit (680,220)  (545,200)
Total stockholders’ equity 376,856   200,493 
Total liabilities and stockholders’ equity$513,600  $355,598 
    

FAQ

What were Nurix Therapeutics' (NRIX) key financial results for Q3 fiscal 2024?

Nurix reported collaboration revenue of $12.6 million, R&D expenses of $55.5 million, and a net loss of $49.0 million or ($0.67) per share for Q3 fiscal 2024.

What clinical progress did Nurix Therapeutics (NRIX) report in Q3 fiscal 2024?

Nurix initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia and other B-cell malignancies, and reinitiated enrollment for NX-2127 in a Phase 1a/b oncology trial.

What is Nurix Therapeutics' (NRIX) cash position as of August 31, 2024?

Nurix reported cash, cash equivalents, and marketable securities of $457.5 million as of August 31, 2024.

What upcoming milestones does Nurix Therapeutics (NRIX) anticipate?

Nurix anticipates clinical data readouts in Q4 2024 and plans to initiate pivotal studies for NX-5948 in 2025.

Nurix Therapeutics, Inc.

NASDAQ:NRIX

NRIX Rankings

NRIX Latest News

NRIX Stock Data

1.77B
70.84M
1.9%
103.8%
14.47%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO